Skip to main content
Spero Cataland, MD, Hematology, Columbus, OH, Ohio State University Wexner Medical Center

SperoRickCatalandMD

Hematology • Columbus, OH

Professor of Medicine, Ohio State University

Join to view full profile

Dr. Cataland is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Cataland's full profile

Already have an account?

Education & Training

  • University of Chicago
    University of ChicagoFellowship, Hematology and Medical Oncology, 1997 - 2000
  • Ohio State University Hospital
    Ohio State University HospitalResidency, Internal Medicine, 1994 - 1997
  • Ohio State University College of Medicine
    Ohio State University College of MedicineClass of 1994

Certifications & Licensure

  • OH State Medical License
    OH State Medical License 1995 - 2025
  • IL State Medical License
    IL State Medical License 1997 - 2002
  • American Board of Internal Medicine Hematology

Awards, Honors, & Recognition

  • Regional Top Doctor Castle Connolly, 2014
  • CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • The Role of ADAMTS13 Testing in the Diagnosis and Management of Thrombotic Microangiopathies and Thrombosis  
    Spero R Cataland, Camila Masias, Blood

Abstracts/Posters

  • African American Race Is Associated with Decreased Relapse-Free Survival in Immune Thrombotic Thrombocytopenic Purpura
    Spero Cataland, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
  • A Pilot Study on Biomarkers of Vascular Injury in Patients with Immune-Mediated Thrombotic Thrombocytopenic Purpura
    Spero Cataland, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
  • Discordance between Free C5 and CH50 Complement Assays in Measuring Complement C5 Inhibition in Patients with aHUS Treated with Ravulizumab
    Spero Cataland, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
  • Join now to see all

Lectures

  • Aware of the Rare: Diagnosing and Treating Immune-Mediated Hematologic Disorders 
    61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
  • Adult Clinical Non-Malignant Hematology 
    61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
  • Risk Factors and Manageability of the Mainly Mild Mucocutaneous Bleeding Profile Observed in Attp Patients Treated with Caplacizumab during the Phase III Hercules Study 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

  • Cost Is the Main Hurdle to Broad Use of Caplacizumab for TTP
    Cost Is the Main Hurdle to Broad Use of Caplacizumab for TTPDecember 7th, 2020
  • Ultomiris Receives Approval for Atypical Hemolytic Uremic Syndrome
    Ultomiris Receives Approval for Atypical Hemolytic Uremic SyndromeOctober 22nd, 2019
  • Alexion Receives FDA Approval for ULTOMIRIS® (Ravulizumab-Cwvz) for Atypical Hemolytic Uremic Syndrome (aHUS)
    Alexion Receives FDA Approval for ULTOMIRIS® (Ravulizumab-Cwvz) for Atypical Hemolytic Uremic Syndrome (aHUS)October 18th, 2019
  • Join now to see all

Hospital Affiliations

Dr. Spero Cataland, Dr. Spero Cataland, MD, Dr. S Cataland, Dr. Spero Rick Cataland